Somewhat Positive Media Coverage Somewhat Unlikely to Affect BioTelemetry (BEAT) Stock Price

Media coverage about BioTelemetry (NASDAQ:BEAT) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.8747512995534 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities analysts have recently commented on BEAT shares. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. Dougherty & Co reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioTelemetry in a report on Wednesday, November 8th. BidaskClub raised shares of BioTelemetry from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Raymond James Financial started coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price on the stock. Finally, SunTrust Banks started coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $42.86.

BioTelemetry (BEAT) traded up $0.60 during trading hours on Friday, reaching $31.65. 350,697 shares of the company were exchanged, compared to its average volume of 429,205. BioTelemetry has a 1 year low of $23.30 and a 1 year high of $39.20. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. The stock has a market cap of $1,010.00, a price-to-earnings ratio of 24.16, a price-to-earnings-growth ratio of 1.38 and a beta of 0.67.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The firm had revenue of $81.02 million during the quarter, compared to analysts’ expectations of $82.10 million. During the same quarter last year, the business earned $0.21 earnings per share. The business’s quarterly revenue was up 52.7% on a year-over-year basis. equities research analysts anticipate that BioTelemetry will post 0.83 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect BioTelemetry (BEAT) Stock Price” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at

BioTelemetry Company Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Insider Buying and Selling by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit